Results 181 to 190 of about 26,857 (227)

Resistance to HIV integrase inhibitors

Current Opinion in HIV and AIDS, 2012
HIV integrase inhibitors are potent antiretroviral drugs that efficiently decrease viral load in patients. Emergence of resistance mutations against this new class of drugs represents a threat to their long-term efficacy. The purpose of this review is to provide new information about the most recent mutations identified and other mutations that confer ...
Thibault, Mesplède, Peter K, Quashie, Mark A, Wainberg   +2 more
openaire   +4 more sources

HIV integrase inhibitors: a new era in the treatment of HIV

Expert Opinion on Pharmacotherapy, 2015
Integrase inhibitors (INIs) are the latest class of antiretroviral drugs approved for the treatment of HIV infection and are becoming 'standard' drugs in the treatment of both naïve as well as heavily pretreated individuals with HIV.Data on efficacy, safety, tolerability, pharmacokinetics, drug-drug interactions and resistance are reviewed from the ...
Gary Whitlock, Ana Milinkovic
exaly   +3 more sources

Targeting HIV-1 integrase

Expert Opinion on Therapeutic Targets, 2001
Human immunodeficiency virus Type 1 (HIV-1) integrase is an essential enzyme for the obligatory integration of the viral DNA into the infected cell chromosome. As no cellular homologue of HIV integrase has been identified, this unique HIV-1 enzyme is an attractive target for the development of new therapeutics.
Khampoune, Sayasith, Gilles, Sauvé, Jocelyn, Yelle   +2 more
openaire   +2 more sources

Tolerability of HIV integrase inhibitors

Current Opinion in HIV and AIDS, 2012
This review discusses the available safety data for three integrase strand transfer inhibitors (INSTIs)--raltegravir, elvitegravir and dolutegravir--derived from studies in both HIV-infected and HIV-uninfected cohorts.Phase 2 and 3 clinical trials show that all three INSTIs are well tolerated in treatment-naive and treatment-experienced patients with ...
Frederick J, Lee, Andrew, Carr
openaire   +2 more sources

Integrase inhibitors to treat HIV/Aids

Nature Reviews Drug Discovery, 2005
HIV integrase is a rational target for treating HIV infection and preventing AIDS. It took approximately 12 years to develop clinically usable inhibitors of integrase, and Phase I clinical trials of integrase inhibitors have just begun. This review focuses on the molecular basis and rationale for developing integrase inhibitors.
Yves Pommier, Allison A Johnson, Christophe Marchand   +2 more
exaly   +3 more sources

Novel integrase inhibitors for HIV

Expert Opinion on Investigational Drugs, 2010
Integrase inhibitors are the newest class of antiretroviral agents developed to treat HIV-1 infection. Raltegravir (RAL), the only integrase inhibitor (INI) currently approved for the treatment of HIV-infected patients, has proven to be a potent and well-tolerated antiretroviral (ARV) agent.
Nicole, Prada, Martin, Markowitz
openaire   +2 more sources

Potential Inhibitors of HIV Integrase

Nucleosides and Nucleotides, 1999
In the search for inhibitors of HIV integrase, the enzyme involved in the integration of viral DNA into host DNA, we have synthesized and studied a number of analogs of the heterocyclic molecule, chloroquine.
C, Mathé, V, Nair
openaire   +2 more sources

HIV Integrase Structure and Function

1999
HIV integrase consists of three domains, the structures of which have been individually determined by X-ray crystallography or NMR spectroscopy. The core domain, spanning residues 50-212, is responsible for the catalytic activity of the enzyme.
D, Esposito, R, Craigie
openaire   +2 more sources